Objectives: Evaluation of the effect of 3 months therapy
of metfonnin/omega-3 (MIO) combination on body mass
index (BMI), insulin resistance (IR), and oxidative and
inflammatory milieu in PCOS women at probable
cardiac risk (CR) as predicted by the atherogenic index
of plasma (All)).
Patients and methods: 90 PCOS women were randomly
allocated Into the M group received metfonnin (500 mg
bi-daily) and WO group received metfonnin (500 mg bidaily) and Omega3 (950 mg active omega-3 once daily).
Pre- and Post-treatment BMI, Homeostasis model
assessment for IR (HOMA-IR), AIP and serum tumor
necrosis factor-u (TNF-u), interleukin (IL)-ß, superoxide
dismutase (SOD), and malondialdehyde (MDA) levels
were evaluated. The primalY outcome is the effect of
provided 3-m therapy AIP.
Results: Pre-treatment AIP defined 15.6% and 58.9% of
studied women had high or intermediate cardiac risk
(CR), 59 women were obese, 16 women were morbidly
obese, and 52 women were insulm resistant with
elevated serum levels ofTNF-u, IL-113, MDA, and
lower serum SOD levels. Combined therapy allowed a
significant decrease in HOMA-IR score, semm TNF-u,
IL- 113, and MDAlevels with significant elevation of
serum SOD. Combination therapy sigmficantly reduced
the AIP m comparison to pre-treatment AIP and to that
of women of the M group. Moreover, no woman still had
high CR after WO therapy and the frequency of women
who had low CR was increased by about 107%.
Conclusion: Insulin sensitizers could improve PCOSassociated disturbances. However, omega-3 adjuvant
therapy significantly augmented the effects of insulin
sensitizers, mmmnzed the cardiac risk factors, and
decreased the risk of probable cardiac events.